Cefepime versus ceftazidime + amikacin as empirical therapy for febrile neutropenia in children with cancer: A prospective randomized trial of the treatment efficacy and cost

Pediatric Hematology and Oncology

Volumn 22, Issue 1, 2005, Pages 59-70

  Çorapçioǧlu, Funda ^a,b   Sarper, Nazan ^a  

^a KOCAELI UNIVERSITY   (Turkey)

^b Department of Pediatric Hematology ^*  (Turkey)

Author keywords

Cancer; Cefepime; Ceftazidime; Children; Febrile neutropenia

Indexed keywords

AMIKACIN; AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; CEFEPIME; CEFTAZIDIME; FLUCONAZOLE; GLYCOPEPTIDE;

ADOLESCENT; ARTICLE; CALCULATION; CANCER PATIENT; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COST; DRUG EFFICACY; EMPIRICISM; FEBRILE NEUTROPENIA; FEMALE; HEALTH CARE COST; HUMAN; INFANT; INFECTION; MALE; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; HOSPITAL COSTS; HUMANS; MALE; NEOPLASMS; NEUTROPENIA;

EID: 11144223035     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.1080/08880010590896297     Document Type: Article

References (28)

1. Hughes WT, Armstrong D, Bodey GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730-751.
2. Gaya H. Empirical therapy of infections in neutropenic patients. Br J Hematol. 101:5-9.
3. Klastersky J. Empirical antibiotic therapy in neutropenic cancer patients. Eur J Cancer. 1993;29:6-10.
4. Biron P, Fuhrmann C, Cure H, et al. Cefepime versus imipenem-cilastatin as emprical monotherapy in 400 febrile patients with short duration neutropenia. J Antimicrob Chemother. 1998;42:511-518.
5. Ramphal R. Is monotherapy for febrile neutropenia still a viable alternative? Clin Infect Dis 1999;29:508-514.
6. Ramphal R, Gucalp R, Rotstein C, Cimino M, Oblon D. Clinical experince with single agent and combination regimens in the management of infection in the febrile neutropenic patient. Am J Med. 1996;100:83S-89S.
7. Kessler RE. Cefepime microbiologic profile and update. Pediatr Infect Dis J. 2001;20:331-336.
8. Jandula BM, Martino R, Gurgi M, Manteiga R, Sierra J. Treatment of febrile neutropenia with cefepime monotherapy. Chemotherapy. 2001;47:226-231.
9. Yamamura D, Gucalp R, Carlisle P, Cimino M, Roberts J, Rotstein C. Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropienic cancer patients. Antimicrob Agents Chemother. 1997;41:1704-1708.
10. Chuang W, Hung IJ, Yang CP, Jaing TH, Lin TY, Huang YC. Cefepime versus ceftazidime as empiric monotherapy for fever and neutropenia in children with cancer. Pediatr Infect Dis J. 2002;21:203-209.
11. Mustafa MM, Carlson L, Tkaczewski I, McCracken GH Jr, Buchanan GR. Comparative study of cefepime versus ceftazidime in the empiric treatment of pediatric cancer patients with fever and neutropenia. Pediatr Infect Dis J. 2001;20:362-369.
12. Agaoglu L, Devecioglu O, Anak S, et al. Cost effectiveness of cefepime + netilmicin or ceftazidime + amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey. J Chemother. 2001;13:281-287.
13. Kebudi R, Gorgün O, Ayan I, Gurler N, Akici F, Toreci K. Randomized comparison of cefepime versus ceftazidime monotherapy for fever and neutropenia in children with solid tumors. Med Pediatr Oncol. 2001;36:434-441.
14. Viscoli C, Castagnola C. Planned progressive antimicrobial therapy in neutropenic patients. Br J Hematol. 1998;102:879-888.
15. Barradell LB, Bryson HM. Cefepime: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1994;47:471-505.
16. Cordonnier C, Herbrecht R, Pico JL, et al. Cefepime/amikacin versus celtazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. The French Cefepime Study Group. Clin Infect Dis. 1997;24:41-51.
17. Klaassen RJ, Goodman TR, Pham B, Doyle JJ. "Low risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol. 2000;18:1012-1019.
18. Erman M, Akkova M, Akan H, et al. Febril neutropenia study group of Turkey. Scand J Infect Dis. 2001;33:827-831.
19. Van Leathem Y, Lagast H, Klastersky J. Serum bactericidal activity of ceftazidime and cefoperazone alone or in combination with amikacin against Pseudomonas aeruginosa and Klebsiella pneumoniae. Antimicrob Agents Chemother. 1983;23:435-439.
20. Pizzo PA. Evaluation of fever in the patients with cancer. Eur J Cancer. 1989;25:9-16.
21. Viscoli C, Castagnola E. Treatment of febrile neutropenia: what is new? Curr Opin Infect Dis. 2002;15:377-382.
22. Quadri TL, Brown AE. Infectious complications in the critically ill patient with cancer. Semin Oncol. 2000;27:335-346.
23. Erjavec Z, de Vries-Hospers HG, Laseur M, Haile RM, Daenen S. A prospective, randomised double blinded, placebo-controlled trial of empirical teicoplanin in febrile neutropenia with persistent fever after imipenem monotherapy. J Antimicrob Chemother. 2000;45:843-849.
24. Cometta A, Kern WV, De Bock R, et al. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis. 2003;37:382-389.
25. Mullen CA, Petropoulos D, Roberts WM, et al. Economic and resource utilization analysis of out-patient management of fever and neutropenia in low-risk pediatric patients with cancer. J Pediatr Hematol Oncol. 1999;21:212-218.
26. Rosenman M, Madsen K, Hui S, Breitfeld PP. Modeling administrative outcomes in fever and neutropenia: clinical variables significantly influence lenght of stay and hospital charges. J Pediatr Hematol Oncol. 2002;24:263-268.
27. Leese B, Collin R, Clark DJ. The cost of treating febrile neutropenia in patient with malignant blood disorders. Pharmacoeconomics. 1994;6:233-239.
28. Dranitsaris G, Tran TM, McGeer A, Narine L. Pharmacoeconomic analysis of emprical therapy with ceftazidime alone or combination antibiotics for febrile neutropenia in cancer patients. Pharmacoeconomics. 1995;7:49-62.